New drug BM230 enters first human trials for advanced cancers
Disease control
Recruiting now
This early-phase study tests a new drug called BM230 in people with advanced solid tumors that are linked to HER2. The goal is to find a safe dose and check for side effects. About 123 participants will take part, first in a dose-finding stage, then in a stage that looks more clo…
Phase: PHASE1 • Sponsor: Suzhou Biomissile Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC